ID   BEC2
AC   CVCL_RQ14
SY   BEC-2
DR   ATCC; HB-10153
DR   Wikidata; Q54795957
RX   Patent=US5529922;
RX   PubMed=2056117;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10153.
CC   Characteristics: Was investigated under the name Mitumomab for the treatment of small cell lung carcinoma in combination with BCG vaccination.
CC   Monoclonal antibody isotype: IgG2b, kappa.
CC   Monoclonal antibody target: Anti-idiotypic against monoclonal antibody R24.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2199 ! Sp2/0-Ag14
CA   Hybridoma
DT   Created: 05-03-18; Last updated: 21-03-23; Version: 4
//
RX   Patent=US5529922;
RA   Chapman P.B., Houghton A.N.;
RT   "Anti-idiotypic monoclonal antibody that induces an immune response
RT   against the ganglioside GD3 and hybridoma producing said antibody.";
RL   Patent number US5529922, 25-Jun-1996.
//
RX   PubMed=2056117; DOI=10.1172/JCI115276;
RA   Chapman P.B., Houghton A.N.;
RT   "Induction of IgG antibodies against GD3 ganglioside in rabbits by an
RT   anti-idiotypic monoclonal antibody.";
RL   J. Clin. Invest. 88:186-192(1991).
//